- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
XARELTO® is the only new oral anticoagulant with FDA approval in this indication
Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies
Unified Janssen companies around the world continue commitment to patients and to addressing unmet medical needs
DACOGEN® (decitabine) showed an overall survival advantage compared with the accepted standard therapies in older patients with newly diagnosed de novo or secondary acute myeloid leukemia
Data from DACO-016 study at 2011 American Society of Clinical Oncology Annual Meeting
Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells As Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
Study utilized Veridex’s CELLSEARCH® CTC Test, the only regulatory-cleared in vitro diagnostic test to capture and count CTCs
Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches
* * *In process of launching 6 key pharmaceuticals products since 2009* * *Executing therapeutic area strategy and advancing key compounds in pipeline* * *Leveraging global market strategies using local insights to successfully grow market share and expand geographic presence* * *
Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise In The Treatment Of Active Rheumatoid Arthritis
Sirukumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis in Patients with Active Disease Despite Treatment with Methotrexate